Although current hypertension management guidelines recommend increasingly stringent blood pressure targets, these targets are seldom achieved in clinical practice. Even in patients with mild-to-moderate hypertension, monotherapy is only effective in approximately 50-70% of patients, and thus there is a clear need for combination therapy if stringent blood pressure targets are to be achieved. Drugs used in combination therapy should satisfy a number of prerequisites, including complementary mechanisms of action, enhanced efficacy in combination, and maintained (or improved) tolerability. Evidence is accumulating that combination therapy with an AT 1 -receptor blocker and a diuretic represents a rational and effective treatment option. In clinical trials, the combination of candesartan cilexetil, 16 mg, and hydrochlorothiazide, 12.5 mg, has been shown to be more effective in lowering blood pressure than either agent alone. Furthermore, this combination
Introduction: the need for combination therapy
In clinical practice, the aims of antihypertensive therapy can be considered to be 'normal' or optimal blood pressure control, and the prevention of complications, without impairing quality of life. The need for normal or optimal blood pressure control is reflected in the latest hypertension management guidelines issued by the World Health Organization and the International Society of Hypertension, which recommend stringent blood pressure targets, of below 130/85 mm Hg in young or middle-aged patients or patients with diabetes, and below 140/90 mm Hg in older patients. 1 However, despite the availability of such guidelines, and a wide range of antihypertensive therapies, blood pressure control remains poor in a majority of patients. In particular, systolic blood pressure is generally poorly controlled in clinical practice. For example, data from the CardioMonitor  survey, which included more than 1300 physicians in five European countries, has been shown to reduce blood pressure to a greater extent, and control blood pressure in a higher proportion of patients, than the combination of losartan, 50 mg, and hydrochlorothiazide, 12.5 mg, both when used instead of or in addition to previous antihypertensive therapy. The placebo-like tolerability of AT 1 -receptor blockers was maintained when these drugs were used in combination with hydrochlorothiazide. The combination of candesartan and a dihydropyridine calcium antagonist has also been shown to be more effective than either component alone. Furthermore, in the Candesartan and Lisinopril Microalbuminuria (CALM) Study, the combination of candesartan and lisinopril reduced blood pressure to a greater extent than either agent alone, and tended to have a greater effect on microalbuminuria. indicate that the proportion of patients in whom diastolic blood pressures below 90 mm Hg were achieved increased from 36% in 1992 to 59% in 1998, but the proportion of patients achieving a systolic blood pressure of below 140 mm Hg remained low (12-21%) during this period. 2 Similarly, data from a number of countries worldwide indicate that at best only about a quarter of patients achieve the blood pressure targets recommended in national guidelines. 3 There is, therefore, a continuing need for new antihypertensive treatment strategies if the goal of optimal blood pressure control is to be achieved.
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Rationale for combination therapy in hypertension
Hypertension is a heterogeneous condition in which both genetic and environmental factors contribute to varying extents. This heterogeneity partly explains the considerable variation in response to antihypertensive therapy seen between individual patients. 4 Due to this heterogeneity, monotherapy with any antihypertensive agent is unlikely to control blood pressure adequately in more than 50-60% of patients, even in mild-to-moderate (Stage 1 or 2) hypertension. In one study, for example, 1292 men with untreated diastolic blood pressures of 95-109 mm Hg were randomised to receive one of six antihypertensive therapies: hydrochlorothiazide, 12.5-25 mg/day, atenolol, 25-100 mg/day, captopril, 25-100 mg/day, clonidine, 0.2-0.6 mg/day, sustained-release diltiazem, 120-360 mg/day, or prazosin, 4 -20 mg/day. 5 These patients were studied in specialist blood pressure clinics, with extensive follow-up. Even under these favourable conditions, however, the proportion of patients achieving and maintaining a diastolic blood pressure of below 95 mm Hg for 1 year ranged from only 50% with captopril to 72% with diltiazem. Similar response rates have been reported in studies with AT 1 -receptor blockers used as monotherapy. 6, 7 A number of factors contribute to inadequate blood pressure control with monotherapy. In particular, non-compliance is common during antihypertensive therapy, and this may be largely driven by poor tolerability. 8 However, recent data indicate that compliance may be improved with AT 1 -receptor blockers, which have an outstanding tolerability profile. 9, 10 Poor blood pressure control during monotherapy may also be related to physiological factors such as the activation of counter-regulatory mechanisms, volume overload, the development of secondary hypertension, or the existence of a high pretreatment blood pressure.
There is good evidence from the Hypertension Optimal Treatment (HOT) Study 11 that the increasingly low blood pressure targets recommended in international guidelines can be readily achieved with simple combination therapy regimens. In this study, 18 790 hypertensive patients were randomised to diastolic blood pressure targets of 90 mm Hg, 85 mm Hg or 80 mm Hg or below. Felodipine was used as first line antihypertensive therapy, and angiotensin converting enzyme (ACE) inhibitors, ␤-blockers and hydrochlorothiazide added according to a fixed protocol as needed to achieve the target blood pressure. The mean diastolic blood pressures achieved were 85.2 mm Hg in the р90 mm Hg target group, 83.2 mm Hg in the р85 mm Hg target group, and 81.1 mm Hg in the р80 mm Hg target group; overall, 92% of patients achieved diastolic blood pressures of 90 mm Hg or below. The majority of patients required combination therapy to achieve their blood pressure targets. In the subset of previously treated patients, only 41% were receiving combination therapy at enrolment, and the mean blood pressure was 161/98 mm Hg. At the end of the study, the proportion of patients receiving combination therapy had increased to 68%, and the mean blood pressure had decreased to 142/83 mm Hg (Figure 1) .
Combination therapy offers a number of potential benefits in hypertension. The use of drugs with complementary mechanisms of action should lead to additive reductions in blood pressure with maintained or even improved tolerability. An important reason for the latter is that one drug could oppose the counter-regulatory mechanisms triggered by the other drug, which would otherwise tend to limit the reduction in blood pressure and may also be the cause of side-effects. Furthermore, combination therapy may allow lower doses of each drug to be used, thereby reducing the incidence of dose-related adverse effects and promoting better compliance with treatment. Combination therapy may also produce additive protective effects against target organ damage.
Combinations of ␤-blockers with diuretics or dihydropyridine calcium antagonists, or ACE inhibitors with diuretics, are widely accepted in clinical practice. In addition, there is now good evidence from recent studies that the combination of an AT 1 -receptor blocker and a diuretic represents a rational and effective management strategy in patients whose blood pressure remains uncontrolled despite monotherapy. Evidence is also emerging that combinations of AT 1 -receptor blockers with calcium antagonists or ACE inhibitors may be beneficial.
Combination therapy with AT 1 -receptor blockers and diuretics
The increase in blood pressure mediated by angiotensin II is principally a response to AT 1 -receptor activation, which results in vasoconstriction, aldosterone release, and activation of the sympathetic nervous system leading to an increase in peripheral resistance. In the longer term, angiotensin II promotes growth and remodelling in the heart and vasculature, which contributes to the development of target organ disease such as congestive heart failure or nephropathy. AT 1 -receptor blockade reduces peripheral resistance and blood pressure, and produces a reflex increase in angiotensin II concentrations leading to activation of AT 2 -receptors, which is believed to oppose the long-term adverse effects of AT 1 -receptor activation in target tissues.
The effects of AT 1 -receptor blockers on blood pressure are particularly marked in younger patients or patients with high plasma renin activity, whereas in elderly patients or patients with low plasma renin activity, such as black patients, diuretics are particularly effective in lowering blood pressure. These agents act by decreasing plasma volume through diuresis, and by reducing the responsiveness of vascular smooth muscle to vasoconstrictors. The reduction in plasma volume, however, leads to counter-regulatory stimulation of the reninangiotensin system and the sympathetic nervous system.
These interactions between diuretics and the renin-angiotensin system underpin the rationale for combination therapy with AT 1 -receptor blockers and diuretics. Low-dose diuretics help to enhance the response to AT 1 -receptor blockers by stimulating the activity of the renin-angiotensin system. Conversely, AT 1 -receptor blockers suppress the adverse effects on blood pressure resulting from activation of the renin-angiotensin system and the sympathetic nervous system. AT 1 -receptor blockers and diuretics thus act in a synergistic and complementary fashion.
Combination therapy with candesartan and hydrochlorothiazide
Complementary features of candesartan and hydrochlorothiazide are listed in Table 1 . The pharmacological properties and clinical efficacy of candesartan make it an ideal combination partner with hydrochlorothiazide. The benefits of combination therapy with candesartan and hydrochlorothiazide in hypertensive patients have been demonstrated in several clinical studies. In a double-blind dose-ranging study, 1096 patients with mild-to-moderate hypertension (sitting diastolic blood pressure 95-110 mm Hg) were randomised to receive once-daily treatment with candesartan cilexetil, 2, 4, 8 or 16 mg, hydrochlorothiazide, 12.5 or 25 mg, combination therapy with both agents at these respective doses, or placebo for 8 weeks. 18 In the 1038 patients who completed the study, reductions in sitting diastolic blood pressure were seen after 1 week with all active treatments except for monotherapy with hydrochlorothiazide, 12.5 mg. At the end of the study, the greatest reduction in sitting blood pressure (−23.0/−16.6 mm Hg) was seen with the combination of candesartan cilexetil, 16 mg, plus hydrochlorothiazide, 12.5 mg (Figure 2 ). Furthermore, this combination produced a significantly greater mean reduction in diastolic blood pressure than the best reduction achieved with either component given as monotherapy (mean difference 6.3 mm Hg vs monotherapy with candesartan, 16 mg; P Ͻ 0.01). The response rates (defined as the proportion of patients showing a reduction in sitting diastolic blood pressure to below 90 mm Hg or a reduction in sitting diastolic blood pressure of at least 10 mm Hg) tended to increase with increasing doses of candesartan, and was highest (85%) in patients receiving the combination of candesartan cilexetil, 16 mg, and hydrochlorothiazide, 12.5 mg.
In a second study, 19 170 patients with mild-tomoderate hypertension (defined as in the previous study) were randomised to receive placebo, candesartan cilexetil, 16 mg, hydrochlorothiazide, 12.5 mg, or the two agents in combination, once daily for 12 weeks. Ambulatory blood pressure monitoring 
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(ABPM) was performed for 24 h before the start of randomised treatment and for 24 h after the final dose. The combination of candesartan cilexetil and hydrochlorothiazide was significantly (P Ͻ 0.05) more effective in controlling diastolic blood pressure than hydrochlorothiazide or placebo (Figure 3) , and also tended to be more effective than candesartan alone (P = 0.083). Furthermore, the reductions in systolic blood pressure achieved with the combination were significantly greater than those achieved with either component given as monotherapy (P Ͻ 0.05).
A further study has investigated the efficacy of combination therapy with candesartan cilexetil and hydrochlorothiazide in 217 patients with severe hypertension (mean blood pressure at screening approximately 165/112 mm Hg). 20 After a 1-week 21 At the end of this period, mean blood pressure had decreased to 132.2/87.1 mm Hg ( Figure 5 ). The greatest reduction was seen in patients receiving the combination of candesartan cilexetil, 16 mg, and hydrochlorothiazide, 12.5 mg, in whom mean blood pressure decreased from 167.1/111.9 mm Hg at the end of the hydrochlorothiazide run-in period to 128.9/88.3 mm Hg at the end of the study. At the end of the study, 87% of patients had responded to treatment.
Comparative studies with AT 1 -receptor blocker combinations
Comparative studies have consistently shown that candesartan is more effective than the prototype AT 1 -receptor blocker, losartan, when used as monotherapy. 7, 22 These differences are consistent with the known differences in pharmacodynamic properties between members of the class (see paper by Gradman in this supplement).
Two recent studies have compared the efficacy of candesartan cilexetil, 16 mg, plus hydrochlorothiazide, 12.5 mg, with that of a combination of losartan, 50 mg, plus hydrochlorothiazide, 12.5 mg. In the first study, 299 hypertensive patients (sitting dias- tolic blood pressure 90-110 mm Hg, systolic blood pressure р200 mm Hg), who had previously received monotherapy with any antihypertensive drug for at least 4 weeks, were randomised to receive candesartan-hydrochlorothiazide or losartan-hydrochlorothiazide for 12 weeks instead of their previous therapy. 23 After 12 weeks, sitting blood pressures, measured 24 h after the last dose, were reduced to a significantly greater extent in patients receiving candesartan-hydrochlorothiazide than in those receiving losartan-hydrochlorothiaJournal of Human Hypertension zide ( Figure 6 ). The mean reductions in systolic and diastolic blood pressures in patients receiving candesartan-hydrochlorothiazide were −19.4 mm Hg and −10.4 mm Hg, respectively, compared with −13.7 mm Hg and −7.8 mm Hg, respectively, in patients receiving the losartan-hydrochlorothiazide combination. The response and control (defined as a diastolic blood pressure of 90 mm Hg or less) rates in patients receiving the candesartan-hydrochlorothiazide combination were significantly higher than in those receiving losartan-hydrochlorothiazide. In the candesartan-hydrochlorothiazide group, the response and control rates were 68.2% and 60.9%, respectively, compared with 56.8% (P = 0.041) and 49.3% (P = 0.044), respectively, in the losartanhydrochlorothiazide group. Thus, the combination of candesartan and hydrochlorothiazide normalised blood pressure in approximately 61% of patients in whom monotherapy had previously been ineffective.
The second study compared the relative efficacy of candesartan cilexetil, 16 mg, plus hydrochlorothiazide, 12.5 mg, and losartan, 50 mg, plus hydrochlorothiazide, 12.5 mg, given in addition to any previous antihypertensive therapy for 6 weeks, in 168 patients with untreated or uncontrolled moderate or severe hypertension (diastolic blood pressure Ͼ100 to р120 mm Hg). 24 At the start of the study, 54% of patients had been receiving monotherapy and 20% were receiving combination therapy; thus, in this study, almost three quarters of the patients had uncontrolled hypertension despite monotherapy or combination therapy. After 6 weeks' treatment, the mean changes in blood pressure, measured 24 h after the last dose, were −32.2/−21.1 mm Hg in patients receiving candesartan-hydrochlorothiazide and −23.8/−14.9 mm Hg in those receiving losartan-hydrochlorothiazide (P Ͻ 0.001; Figure 7) . Furthermore, blood pressure measurements 48 hours after the last dose showed that the candesartan-hydrochlorothiazide combination produces a more sustained antihypertensive effect than losartan-hydrochlorothiazide; mean blood pressure reductions at 48 hours were −25.6/−16.4 mm Hg, compared with −9.2/−4.2 mm Hg, respectively (Figure 7) . The response and control rates (defined as in the previous study), measured 24 h after the last dose, were 98% and 58%, respectively, with candesartan-hydrochlorothiazide, compared with 79% and 28%, respectively, with losartan-hydrochlorothiazide. The corresponding figures 48 h after the last dose were 84% and 37%, respectively, with candesartan-hydrochlorothiazide and 18% and 1.3%, respectively, with losartan-hydrochlorothiazide. Each of these differences between the groups was statistically significant (P Ͻ 0.001).
Tolerability of combination therapy with candesartan cilexetil and hydrochlorothiazide
Clinical trials with the combination of candesartan cilexetil and hydrochlorothiazide have consistently shown that this combination is well tolerated, with an adverse event profile comparable with that of placebo. For example, in the double-blind dose-ranging study described above, 18 the incidence of adverse events was 21-40% in patients receiving the combination, compared with 29-35% in patients receiving candesartan monotherapy, 34 -37% in those receiving hydrochlorothiazide alone, and 28% in the placebo group. Similarly, an analysis of the pooled data from five randomised double-blind trials, involving a total of 1551 patients, showed that the incidence of adverse events and discontinuations due to adverse events were comparable in the combination therapy and placebo groups ( Table 2) . 25 Dizziness tended to be slightly more common in patients receiving the candesartan-hydrochlorothiazide combination than in placebo-treated patients, probably reflecting the greater reductions in blood pressure achieved with the combination. The incidence of adverse events was not related to dose, patients' age or gender.
The two studies that compared the candesartanhydrochlorothiazide and losartan-hydrochlorothiazide combinations did not reveal any significant differences in tolerability between the two combinations. 23, 24 It appears, therefore, that the combination of candesartan cilexetil, 16 mg, and hydrochlorothiazide, 12.5 mg, results in enhanced antihypertensive efficacy while preserving the placebo-like tolerability of AT 1 -receptor blockers.
Combinations of candesartan and other antihypertensive agents
A recent study has investigated the effect of combination therapy with candesartan and the dihydropyridine calcium antagonist felodipine in elderly patients (over 65 years of age) with systolic hypertension. 26 A total of 36 patients received candesartan cilexetil, 16 mg, felodipine, 5 mg, the two agents in combination, or placebo for 4 weeks each according to a randomised crossover protocol; 32 patients completed the study. Blood pressure was measured by 24-h ABPM. All three active treatments significantly reduced blood pressure, compared with placebo. However, the combination of candesartan and felodipine had an additive effect on blood pressure, producing significantly greater reductions in 24-h blood pressure than either agent alone; the mean reduction in 24-h systolic blood pressure was 21 mm Hg with the combination, compared with 12.2 mm Hg and 11.9 mm Hg in patients receiving monotherapy with candesartan and felodipine, respectively.
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In this study, 14 patients had microalbuminuria at baseline, and urinary albumin excretion was measured in these patients during each treatment period. 27 The mean albumin excretion rate during placebo treatment was 192 g/min. This decreased to 101 g/min during treatment with candesartan alone, and to 93 g/min during treatment with the combination of candesartan and felodipine; albumin excretion remained largely unchanged (mean 181 g/min) during monotherapy with felodipine. The effects of candesartan, alone or in combination, were significantly greater than that of felodipine monotherapy. Importantly, there was no correlation between changes in microalbuminuria and reductions in blood pressure, which suggests that the decrease in microalbuminuria during candesartan treatment reflects some specific effect of candesartan.
A second study compared the antihypertensive effect of candesartan cilexetil, 8 mg, amlodipine, 5 mg, and the two agents in combination. 28 After 8 weeks, blood pressure was reduced to a significantly greater extent in patients receiving combination therapy than in patients receiving either agent as monotherapy.
In the Candesartan and Lisinopril Microalbuminuria (CALM) Study, 199 hypertensive patients with type 2 diabetes were randomised to receive monotherapy for 12 weeks with either candesartan cilexetil, 16 mg, or lisinopril, 20 mg, after which they either continued on monotherapy or received both agents in combination for a further 12 weeks. 29 Both candesartan and lisinopril produced significant reductions in blood pressure, compared with baseline, at 12 weeks; the mean reductions were −12.4/−9.5 mm Hg and −15.7/−9.7 mm Hg, respectively, and there was no significant difference between the two treatments. After 24 weeks, how-ever, the reduction in blood pressure in patients receiving combination therapy was significantly greater than that in patients receiving monotherapy with either agent. The mean reduction in blood pressure in patients receiving combination therapy was −25.3/−16.3 mm Hg, compared with −14.1/−10.4 mm Hg in patients receiving candesartan alone and −16.7/−10.7 mm Hg in those receiving lisinopril alone. Microalbuminuria was reduced by both monotherapy and combination therapy, with the combination appearing to be the most effective treatment; these results are described in more detail in the paper by Mogensen in this supplement.
Conclusions
Clinical studies and population surveys have clearly shown that a substantial gap exists between the blood pressure targets set out in current hypertension management targets and those achieved in routine clinical practice. Given the limited efficacy of monotherapy, combination therapy has a vital role to play if this gap is to be reduced.
Evidence is accumulating that combination therapy with candesartan and hydrochlorothiazide is a rational and effective approach to hypertension management. Clinical trials have shown that the combination of candesartan and hydrochlorothiazide produces a further reduction in blood pressure in patients in whom blood pressure is not adequately controlled by monotherapy. Comparative studies have shown that the candesartanhydrochlorothiazide combination is significantly more effective than losartan-hydrochlorothiazide, reflecting the differences in efficacy seen when these two AT 1 -receptor blockers are used as monotherapy. Importantly, the enhanced efficacy of the candesartan-hydrochlorothiazide combination is achieved without compromising the placebo-like tolerability profile of AT 1 -receptor blockers. This good tolerability is likely to prove important in enhancing patient compliance with therapy.
Clinical trials also show that candesartan can be successfully combined with calcium antagonists, such as felodipine or amlodipine, or with ACE inhibitors such as lisinopril. In each of these cases, combination therapy was found to be more effective than monotherapy.
